Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment.
Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment.
复制标题
维拉普利用于促性腺激素释放激素激动剂治疗期间的潮热。
DOI：
--
复制
发表时间：
1992
影响因子：
2.1
通讯作者：
P. Crosignani
中科院分区：
文献类型：
--
作者：
P. Vercellini;N. Vendola;A. Colombo;C. Passadore;L. Trespidi;P. Crosignani
潮热是促性腺激素释放激素激动剂（GnRHa）引起的最常见症状。我们进行了一项开放性观察性试验，以评价抗多巴胺能药物维拉利必利在减少25名绝经前妇女潮热方面的疗效，这些妇女接受GnRHa治疗子宫内膜异位症（8例受试者）或月经过多（17例受试者）。患者接受戈舍瑞林长效制剂治疗6个月，第3个月加用维拉利必利。2个月时所有女性的潮热都很严重，但在维拉必利给药期间，92%的受试者的频率和强度都有所改善。获得的益处持续至GnRHa治疗结束。
Hot flushes are the commonest symptom induced by gonadotropin-releasing hormone agonists (GnRHa). We performed an open observational trial to evaluate the efficacy of veralipride, an antidopaminergic drug, in reducing hot flushes in 25 premenopausal women treated with a GnRHa for endometriosis (8 subjects) or menorrhagia (17 subjects). The patients received goserelin depot for 6 months and veralipride was added for the third month. Hot flushes, severe in all women at 2 months, improved in both frequency and intensity in 92% of the subjects during veralipride administration. The benefit obtained persisted until the end of the GnRHa treatment.